What is the difference between VX-770 and VX-809?
VX-770 and VX-809 are two individual therapies being evaluated in separate clinical trials, as well as in combination. VX-770 is more advanced in clinical development and is currently in Phase 3 clinical trials. VX-770 is designed to allow CFTR proteins located at the cell surface to function correctly and improve the flow of salt and fluids in and out of the cell. VX-809 completed a Phase 2a clinical trial in early 2010. VX-809 is designed to move defective CFTR to its proper place in the cell. In the fall of 2010, Vertex launched a Phase 2a trial examining combinations of VX-809 and VX-770 in CF patients.